Article Text

Download PDFPDF

Synovial mast cell responses during clinical improvement in early rheumatoid arthritis


OBJECTIVES To determine the synovial mast cell response in early rheumatoid arthritis (RA) during clinical improvement, and to examine for relations with clinical and histological parameters of disease activity.

METHODS Twenty two synovial samples were obtained from six patients with RA using needle arthroscopy. The mean disease duration at baseline was eight months, and two to three further samples were obtained over a mean follow up period of 15 months during which treatment initiated clinical improvement occurred. Sections were immunostained to detect MCT and MCTC mast cells and correlations were sought between clinical and histological data.

RESULTS The overall mean synovial mast cell density was 40.3 cells/mm2, with regional densities of 60.6 and 34.2 mast cells/mm2 in the superficial and deeper synovial layers respectively. The MCT subset predominated, outnumbering MCTC by 3:1. There was a significant correlation between the histological inflammation index and the MCT density, (r = 0.4, p < 0.05) but not the MCTC subset. The regional distribution and predominant subset of mast cells varied in individual patient’s synovia over time, with a trend towards restriction of the mast cell response to the superficial synovium during clinical improvement.

CONCLUSIONS The mast cell response in early RA is characterised by substantial expansion of predominantly MCTmast cells that correlates with histological indices of inflammation. During clinical improvement, this expansion tended to become more superficial. Taken together with previous studies of long duration RA, which implicate MCTC cells in synovial damage and disease progression, these results suggest that MCT and MCTC mast cells may possess distinct functions in the spectrum of inflammatory events occurring during RA.

Statistics from

There is increasing interest in the role of mast cells in the inflammatory process1 and in the synovitis of rheumatoid arthritis (RA) in particular.2-5 Human mast cells are classified on immunohistochemical staining into two subsets based on their neutral proteinase content.6 7 One subset, MCTC, is named because it contains tryptase and chymase whereas the other, MCT, contains tryptase but not chymase. There is some evidence to suggest that these subsets are functionally distinct. Mast cell subsets localise to different areas of normal tissue: MCTC are the predominant type found in skin and bowel submucosa, whereas MCT are the predominant type in the interalveolar septa of lung and in mucosa of bowel. Whereas both subsets produce tryptase enzymes, MCTC contain, in addition to chymase, carboxypeptidase A,8 and a chymase-like proteinase, cathepsin G,9 which is also present in neutrophils and monocytes. Bradding et al 10have shown that mast cell subsets in asthmatic lung have different cytokine profiles with the MCTC predominantly containing interleukin 4 (IL4) whereas MCT preferentially produce IL5 and IL6, as well as some IL4.

Human mast cells differ in their response to various secretagogues. For example, C5a or compound 48/80 activate skin MCTC mast cells, whereas lung MCT cells are not responsive to these stimuli.11 Substance P and morphine activate skin MCTC cells but not heart mast cells (>90% MCTC) nor lung mast cells. Mast cells purified from predominantly osteoarthritic synovia (reported to be >90% MCTC) were unresponsive to C5a, but were activated by substance P.12 Thus, there is heterogeneity with respect to activation stimuli within the MCTC subset. The distribution of mast cell subsets within tissues is changed in disease states. Patients with the acquired immunodeficiency syndrome and those with combined immunodeficiency diseases have a selective deficiency of MCT in the small bowel,13 whereas patients with inflammatory skin conditions14 or scleroderma have infiltration of MCT cells into the skin.15

We recently defined certain aspects of the mast cell response in RA of relatively long disease duration.4 The mast cell density in RA was increased compared with synovium from normal and osteoarthritic joints. In RA, MCTC cells were associated with areas of cellular, dense fibrous connective tissue, and were present in highest density in patients who had more severe or rapidly progressive disease. The MCT subset was associated with areas of inflammatory cell infiltration, although a correlation with an assessment of the degree of synovitis was not found. There was variability in the response between patients: some samples exhibited exclusive expansion of MCT cells, others only MCTC, whereas most showed expansion of both. This finding raised the question of whether the type of mast cell response is fixed in certain people, or whether it changes depending upon the inflammatory processes occurring in the synovium at different time points.

The aims of this study were to examine the mast cell density and subset distribution in early RA where the articular cartilage is still intact; to determine whether the mast cell response changes in the same patient over time, in particular during clinical improvement; and to further characterise the significance of the MCT and MCTC subsets in relation to the local inflammatory process and the clinical state of the disease. We optimised the detection of the MCTC subset in formalin fixed tissue using avidin and confirm this as a valid technique that can be used on routinely fixed tissue. Analysis was performed on coded tissue sections with the patient identification, clinical details and order of biopsies revealed only after all histological analysis was performed. The early stage of disease and the availability of follow up synovial biopsies have given further insights into potential functional roles of the MCTand MCTC subsets in rheumatoid inflammation.



All patients met the American College of Rheumatology criteria for RA.16 Biopsies of synovium from involved knee joints were performed on six patients within a mean of eight months after first onset of symptoms before treatment with disease modifying drugs. After the start of treatment, each patient had a further two or three biopsies performed over a mean follow up period of 15 months (range 9–24 months). A total of 22 synovial biopsy specimens were available for analysis. Synovial tissue was collected using a needle arthroscope.17 18 Biopsy specimens were taken from areas of clearly visible synovium, usually the medial parapatellar gutter or the suprapatellar pouch. Previous studies have shown little variability in either standard histological19 or immunohistochemical20 findings when multiple samples of synovia taken from different areas of a single joint were compared, validating analysis of a single sample. Furthermore, the histomorphometric system used in this study (see below), analysed a relatively large area of synovium in two regions defined by reference to the synovial surface, which compensated for regional variations in the distribution of mast cells, and ensured valid comparison of values between samples. Follow up biopsy specimens were taken as close as possible to the site of the previous biopsy. Skin specimens were taken from normal areas of excised lesions. Tonsils were taken from routine tonsillectomy. All specimens were fixed in 10% formalin overnight, then embedded in paraffin wax.

The clinical disease activity was assessed at the time of each biopsy by recording patient swollen joints. Blood was collected for C reactive protein (CRP) measurements (mg/l). The assessment of disability used the Health Assessment Questionnaire (HAQ), and pain and overall well being used visual analogue scales. Parameters of clinical disease activity were combined to form a clinical index, and a disease severity index was derived by considering the disability caused by the disease and how quickly this had occurred (HAQ/duration of disease) as previously described.4 Some results from this study were compared with mast cell densities previously reported in synovia taken at the time of arthroplasty or arthroscopy from patients with RA of long duration, (n=16; mean disease duration 18 years), and in synovia taken from normal joints (n = 15; taken at postmortem examination within 12 hours of death).4


Hydrogen peroxide (Ajax Chemicals, Sydney, Australia), mouse monoclonal antihuman tryptase (clone AA1) and polyclonal rabbit anti-CD3 (Dako, Denmark), biotinylated goat antimouse IgG, biotinylated goat antirabbit IgG, peroxidase conjugated streptavidin, avidin-biotin complex conjugated to horseradish peroxidase (ABC-HRP) and goat serum (Vector, Burlingame, CA), proteinase K (Boehringer Manheim, Sydney, Australia), 3-amino-9-ethylcarbazole (Sigma, St Louis, MO), and crystal mount (Biomeda, Foster City, CA) were obtained as indicated. Rabbit immunoglobulin fraction-normal (Dako) and mouse IgG1 negative control monoclonal antibody (Silenus, Melbourne, Australia) were used as negative controls for the various primary antibodies.


Two μm sections of skin and tonsil and 4 μm sections of RA synovium were cut. For each patient, at each time point, adjacent sections were stained for tryptase, with avidin, for CD3 and with haematoxylin and eosin. Sections were digested with proteinase K (10 μg/ml) for 20 minutes at 37°C before immunostaining. Staining for tryptase was performed using the AA1 antibody (1 μg/ml), which is a sensitive and specific marker of mast cells in formalin fixed tissue in which it has been shown to accurately assess mast cell density in direct comparison to Carnoy’s fixed tissue.21 The technique was similar to that used for CD3 as previously described.4 As the anti-chymase antibody we previously used does not reliably stain formalin fixed tissue, we detected chymase containing cells by their ability to bind avidin.22-24ABC-HRP was applied for 30 minutes at room temperature, in the absence of blocking serum, followed by a freshly prepared solution of 3-amino-9-ethyl carbazole (0.4 mg/ml of 0.05M acetate buffer, pH 5) containing 0.01% hydrogen peroxide. Although it has been previously well established that avidin binds only to chymase containing mast cells, and that such binding accurately quantitates mast cell density independent of methods of fixation or embedding,22-24 we confirmed the selectivity of avidin for the MCTC subset by staining serial sections of skin and tonsil fixed in formalin with anti-tryptase and with ABC-HRP. In skin, where more that 99% of all mast cells belong to the MCTC subset,7 ABC-HRP only stained tryptase positive cells (fig 1a and b). In tonsil, ABC-HRP localised to cells in the fibrous tissue septa that were identified on the adjacent section as being tryptase positive. This accords with the known distribution of MCTC cells.7 ABC-HRP did not bind to mast cells beneath the epithelium or around lymphoid follicles where MCT are found (fig 1c and d). Thus, the staining results confirm that avidin in ABC-HRP binds selectively to MCTC and can be used as a quantitative marker for these cells in formalin fixed tissue.

Figure 1

Two μm serial sections of skin (a) (b), tonsil (c) (d), and 4 μm sections of RA synovium (e) (f) (g) (h) were stained for tryptase (a) (c) (e) (g) and with avidin (b) (d) (f) (h). The arrows indicate the synoviocyte lining layer. In skin where > 99% of mast cells are MCTC, all avidin positive cells (b) (cells 1–6) stained for tryptase (a), confirming that avidin detects MCTC mast cells. In tonsil, no avidin positive cells (d) were found beneath the capsule (cap) or around lymphoid follicles where MCT are known to be present (c), indicating that avidin does not bind to MCT mast cells. These staining results are consistent with the known distribution of MCTC within skin and tonsil and validate avidin as a marker of MCTC. Adjacent sections from a patient with RA (e) (f) show MCTCaround subsynovial venules in an area with relatively few lymphocytes and a thin synovial lining layer. The tryptase positive mast cells in (e) also stain with avidin (f). Adjacent sections from another RA patient (g) (h) show MCT around a collection of lymphocytes, underneath a hyperplastic synovial lining layer. Tryptase positive mast cells (g) are not detected with avidin (h), indicating these cells are MCT. Magnification: all at × 500, except (g) (h) at × 312.


The total mast cell population was determined by staining for tryptase, which is found in both MCT and MCTCsubsets. For all samples, the adjacent section was stained with avidin, which localised to the MCTC subset. The density of MCT was derived from these two values. Sections adjacent to the ones stained for mast cells were stained with haematoxylin and eosin. These sections were analysed for synoviocyte hyperplasia, vascularity and perivascular, focal and diffuse infiltration of lymphocytes. Lymphocytic infiltration was confirmed on further sections stained for the pan T cell marker, CD3. These parameters were graded according to the criteria of Rooney et al 19and an inflammation index was derived. The slides remained coded until mast cell densities and histological assessments of synovitis had been performed.

To compensate for variability in inflammation, mast cell density, and other histological parameters that may be present in rheumatoid synovium, a rigorous quantitative histomorphometric system was used, as previously described.4 After staining, the synoviocyte lining layer was identified in each specimen and tissue was analysed to a depth of 1 mm. A large total area of synovium was then analysed, with a mean area of synovial tissue examined in the 22 samples of 4 mm2. The total area was subdivided into two; the superficial layer defined tissue within 100 μm of the intimal layer, and the deeper layer, which comprised the rest of the section. All mast cells within each area analysed were individually counted using a computer based morphometric system4 25 and an Olympus microscope at × 125 magnification.


When examining the correlation between mast cell density and clinical or histological indices of disease severity, the one tailed Pearson’s r test was used. When the mast cell density was compared with that in late RA, the one tailed Student’s ttest was used. One tailed tests were used as we expected to find a positive relation between mast cells and clinical and histological evidence of inflammation.



As the RA synovia were collected from patients with early disease and at follow up, this allowed the results to be analysed in two ways. Firstly, the 22 samples of synovia were grouped together, representing the early RA response at various stages of disease activity. The mast cell response in each sample was compared with histological and clinical data. Secondly, as the 22 samples were taken in a longitudinal fashion from six patients, the mast cell responses before treatment were compared with those after treatment induced clinical improvement.

The overall mean synovial mast cell density in the 22 samples was 40.3 cells/mm2, with regional densities of 60.6 mast cells/mm2 in the superficial layer and 34.2 mast cells/mm2 in the deeper layer (table 1). When mast cell subsets were examined, the MCT subset predominated, outnumbering MCTC cells by 3:1. This ratio was approximately the same in both superficial and deeper layers of the synovium. There was a predominance of MCT over MCTC in the superficial layer of 17 of 21 specimens (in one specimen no mast cells were seen in the superficial layer). Similarly in the deeper layer, MCT predominated in 13 of 22 specimens. MCT were seen in all specimens. In four specimens, no MCTC were seen, resulting in only MCT being present in both superficial and deeper layers of these specimens. Thus, the pattern in early RA was expanded numbers of MCT cells in both superficial and deeper layers.

Table 1

Mean (SD) mast cell density (cells/mm2) in normal synovium, early RA, and late RA

These results were compared with those that we have previously reported in RA synovia from patients with longstanding disease (mean duration = 18 years), and from samples of normal synovium obtained from postmortem examination4 (table 1). There were significant differences in the mast cell responses in early versus late RA. Mast cell density was significantly increased in early RA compared with normal synovium, but was less than the response seen in late RA. Whereas the density of both subsets was substantially increased in late disease compared with normal, the increase in mast cells in early RA was nearly exclusively because of an 18-fold expansion of MCT, with little increase in the MCTC subset. The pattern of response in early versus late RA was identical in the superficial synovial layer. However, there were significantly less total mast cells in the deeper layer in early versus late RA, and this was entirely because of a lack of expansion of MCTC mast cells in this region. Moreover, whereas the typical pattern noted in late RA was MCTpredominating in the superficial layer with MCTC prominent in the deeper layer, in early RA, MCT were predominant in both regions of synovium. Once again, this was because of a relative lack of expansion of MCTC in the deeper layer.


There was a significant correlation between the total mast cell density throughout the synovium and the inflammation index (r = 0.39, p < 0.05) (fig 2a). When mast cell subsets were examined, it was clear that this relation was because of the MCT subset, with a significant correlation between MCT density throughout the tissue and the inflammation index (r = 0.4, p < 0.05) (fig 2b). No correlation was observed between the inflammation index and the MCTCdensity (fig 2c). MCTC were not found in areas with prominent inflammatory changes (fig 1e and f). However, MCTwere frequently found close to infiltrating inflammatory cells, lymphocytes, and areas where the synoviocyte lining layer was hyperplastic (fig 1g and h).

Figure 2

Relation of mast cells to inflammation index. There was a significant correlation between (a) total mast cell density and the inflammation index (r = 0.39, p < 0.05). When mast cell subsets were examined, this relation was because of the MCTsubset, with (b) a significant correlation between MCTdensity and the inflammation index (r = 0.4, p < 0.05). (c) No correlation was observed between the inflammation index and the MCTC density.


All patients improved clinically from the beginning to the end of the study period (table 2). The mean CRP and clinical index decreased from the baseline to final biopsies (60 to 2.7 mg/l and 6.3 to 0.6, respectively, p < 0.05 for both). Furthermore, the inflammation index decreased significantly from 5.1 to 2.7 (p < 0.05). At baseline before treatment with disease modifying drugs, the mast cell density was uniform throughout the synovium being equal in both superficial and deeper layers. During clinical improvement, there was no significant change in the total mast cell density. However, there appeared to be a redistribution of mast cells throughout the synovium with an increase in the mean mast cell density in the superficial layer and a decrease in the deeper layer (table 2). This pattern was confirmed when the changes in individual patients were examined. The mast cell density increased in five patients in the superficial layer, and decreased in five patients in the deeper layer (fig 3). There was a trend showing the increase in the superficial layer was largely because of expansion of the MCT subset and the decrease in the deeper layer because of reduction in the MCTC subset. There was no significant change in the vascularity of the synovial samples during clinical improvement.

Table 2

Comparison of mean (SD) values of the clinical index, CRP (mg/l), inflammation index, and mast cell density (cells/mm2) at baseline and final biopsy time points (n=6)

Figure 3

The changes in synovial mast cell density between final and baseline biopsies. Each point represents the changes seen in the superficial or deeper layers of synovia from patients 1 to 6.

The pattern of mast cell response varied at different timepoints in individual patients. For example, in one patient (fig 4a), the total mast cell density remained stable over the study period. However, the MCT density decreased while there was a reciprocal increase in MCTC density. In this patient, at the baseline, four, and seven month biopsies, there was a predominance of MCTover MCTC, whereas at the 12 month biopsy, the MCTC subset was predominant. In another patient (fig 4b), there was a dramatic reduction in total mast cell density after intravenous methylprednisolone, and over subsequent biopsies there was a progressive increase in the MCT density. These patients demonstrate the pattern seen in four of six patients, where the predominant mast cell subset that was expanded in individual patients did not appear to be a fixed response, but varied over time. In two patients the MCT subset was predominant at all the biopsy time points. In no patient was the MCTC subset predominant at all the biopsy time points.

Figure 4

Individual patient mast cell responses at different time points. In patient (a), the total mast cell density remained stable over the study period. However, the MCT density decreased while there was a reciprocal increase in MCTCdensity. In patient (b), there was a dramatic reduction in total mast cell density after intravenous methylprednisolone, and over subsequent biopsies there was a progressive increase in the MCTdensity.


The six patients were treated with a variety of drugs; two patients received a single intravenous injection of 1 g of methylprednisolone at the onset of treatment, four patients were given gold sodium thiomalate (GST), four were given methotrexate (MTX), and one was treated with sulphasalazine (SSZ). The patients were grouped in a variety of ways according to the effect (overall increase or decrease) on the synovial mast cell density throughout the whole synovial tissue, the superficial or deeper layers. Two patients treated with GST and subsequently changed over to MTX and one patient treated with MTX alone had an increase in the total number of synovial mast cells at the end of the follow up period compared with the baseline biopsy. Two patients treated with intravenous methylprednisolone and GST (one of these patients was given combination treatment with MTX), and one patient treated with SSZ had a fall in mast cell density over the study period. The limited number of patients and the lack of a standardised treatment protocol meant that a predictable pattern of the effect of individual drugs on synovial mast cell density did not emerge.


We recently highlighted the increased synovial mast cell density that occurs in RA of relatively long duration, and noted that the MCTC subset of mast cells was associated with regions in the synovium of “active” fibrosis.4 A correlation between MCTC cells and parameters of rapidly progressive disease suggested that this subset was important in the destructive processes or the resulting repair mechanisms that occur in RA, or both. We noted that some synovia had a predominant expansion of the MCT subset of mast cells, which were often found associated with infiltrating leucocytes. However, it was unclear whether the predominance of one or other mast cell subset was a fixed response in an individual, or whether this reflected the types of inflammatory processes occurring in the synovium.

This study has considered these questions and in addition, has provided new information concerning the mast cell response in early RA, and the changes that occur during clinical improvement. Firstly, we have shown that similar to late RA, the mast cell density was significantly increased in early RA compared with normal synovium. However, in contrast with late RA, the expansion was mostly restricted to the superficial synovial layer, and was because of a selective increase in the MCT subset, the density of which directly correlated with the histological index of inflammation (r = 0.4, p < 0.05) (fig 2b). Secondly, when synovia from the same patients were examined sequentially over time, the mast cell densities changed as did the predominant subset, indicating that RA patients are not committed either to MCT or MCTC subset predominance throughout the course of their disease. The ability of the predominant mast cell subset to change over time suggests that the mast cell response is influenced by factors such as inflammatory cells and their products in the local microenvironment. Thirdly, during clinical improvement in the activity of RA, there were changes in the regional mast cell densities, with an increase in the superficial layer and decrease in the deeper layer. Taken together, these findings highlight that the mast cell response in RA varies at different time points during the disease, perhaps reflecting the spectrum of inflammatory events that occur at different stages of RA.

There has been no previous study of mast cell responses soon after symptom onset with follow up in the early stages of the disease. We were able to report the changes in synovial mast cell responses within a mean of eight months from symptom onset and followed up the same patients with serial biopsies over a 9–24 month period, during treatment induced clinical improvement. Over the follow up period, all patients demonstrated a marked improvement in clinical indices and CRP, reflecting clinical remission of their disease. This was mirrored by a partial improvement in the inflammation indices. However, in no case did the synovium return to normal, indicating that synovitis persists despite clinical resolution. This concords with Soden et al,26 who found inflammatory changes in synovia from clinically uninvolved knee joints in patients with early, active RA.

This study complements and extends the results we have previously published in late RA,4 illustrating that there are important features that differentiate the mast cell response in early and late stages of the disease. In early RA, the MCT:MCTC ratio throughout the synovial tissue was approximately 3:1, whereas in late RA it was 2:3. The key difference was that in early disease, there was a lack of expansion of the MCTC subset that was a prominent finding in late RA (table 1). No specimen in the early RA group had areas of cellular dense fibrous connective tissue that was the hallmark of late RA specimens with high MCTC densities. Thus, when comparing early with late RA, the MCT subset is prominent in early disease and associated with inflammatory cell infiltration, whereas in late disease the MCTC subset is associated with areas of cellular, dense fibrous connective tissue, especially seen in synovia from patients who have severe or rapidly progressive disease.

Although the role of mast cells in rheumatoid inflammation has yet to be defined, two possible functions are participation in matrix turnover and interaction with cells of the adaptive immune system. Mast cells may exert a bi-directional effect on matrix turnover. Mast cell tryptase and chymase have been shown to activate the zymogen forms of the matrix metalloproteinases, prostromelysin, and procollagenase respectively.27 28 On the other hand, mast cells may mediate matrix regeneration as they contain a variety of pro-fibrotic cytokines including bFGF29 and IL410 as well as tryptase, which is mitogenic for cultured fibroblasts.30 Of the two human mast cell subsets, MCTC cells are more likely to be involved in these processes. This subset contains chymase, which in addition to activating procollagenase, has been reported to release matrix bound TGFβ,31 a fibrogenic cytokine, and as noted earlier, MCTC preferentially contain IL4.10 Our previous study of long duration RA,4 in which MCTC mast cells were predominantly expanded in areas of cellular fibrotic synovium, especially in patients who had severe or rapidly progressive disease, would be consistent with a role for MCTC mast cells in matrix turnover.

On the other hand, the MCT subset may be more important in inflammatory events and in interactions with lymphocytes. A dependence on T lymphocyte derived factors has long been recognised for the mucosal subset of murine and rat mast cells,32 and human MCT mast cells are selectively depleted in patients with T lymphocyte immunodeficiency.13 More recent data indicate that mast cells interact with both B and T lymphocytes during bacterial and parasitic infections (reviewed in Mecheri and David33). These interactions include T cell independent stimulation of B cell IgE production,34 and presentation of immunogenic peptides to T cells.35 36 The preferential production of cytokines such as IL4, IL5, and IL6 by MCTcells10 has been postulated to favour THELPERcell differentiation towards a type 2 response.37 This bilateral relation between mast cells and lymphocytes may underlie the association of MCT cells with inflammatory cells, in particular lymphocytes that we observed.

An interesting, but unexpected finding in this study was that during clinical resolution and histological improvement, although the overall mast cell densities did not change significantly, there were consistent changes in the distribution of mast cells. The mean density of mast cells was virtually the same in both superficial and deep synovial layers at baseline when the disease was highly active (43.5 and 47.8 cells/mm2 respectively; n=6) (table 2). However, the mean mast cell density expanded in the superficial layer (from 43.5 to 68.9 cells/mm2) and decreased in the deeper layer (from 47.8 to 26.9 cells/mm2) at the final biopsy when all patients had improved clinically. Although these results are derived from only six paired biopsies, limiting their interpretation, the trends were consistent (fig 3). Four patients showed an increase in the mast cell density superficially combined with a reciprocal decrease in the deep synovium. One patient showed a decrease in both regions, but the decrease in the deeper layer was fourfold greater than that superficially. The final patient showed an increase in both regions but the increase superficially was nearly three times that in the deeper synovium. Thus, in every case, the net effect during clinical improvement was a lessening of the mast cell response in the deep synovium, relative to the response in the superficial synovial layer.

It is possible that clinical treatment in early RA changed the mast cell response predominantly in the deeper layer, preventing expansion of MCTC, which we previously found to be associated with progressive disease in late RA.4 Such a “superficialisation” of the synovial mast cell response may reflect an intermediate stage between mast cell expansion and resolution. Conceivably, mast cell expansion in RA might begin in the superficial synovium after recruitment of mast cell precursors via the subsynovial blood vessels. These mast cell committed progenitors possibly already possess the MCT phenotype,38 39 or will early in their tissue maturation process. As inflammation becomes chronic, and associated with tissue destruction, mast cells may spread into the deeper synovial regions, perhaps differentiating into MCTCcells. With resolution, MCTC may revert back to MCT, and accumulate superficially before gradually exiting from the synovium. The mechanisms underlying mast cell recruitment and differentiation within human tissues are highly controversial, but there is some evidence for such a pathway,40 and considerable evidence for this scenario in the murine system.41 42 In any event, the changes observed in the distribution of mast cell subsets during clinical improvement of RA, illustrate that further studies of the mast cell response in this disease are likely to provide additional information, not only about the role of mast cells in RA, but also about the biology of the mast cell itself.


This work was supported by grants from the Arthritis Foundation of Australia and the National Health and Medical Research Council of Australia.


Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.